trending Market Intelligence /marketintelligence/en/news-insights/trending/X9061ERxBz_Z5FT80CNOsw2 content esgSubNav
In This List

Soligenix, IDT Biologika extend collaboration for biodefense vaccine

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Soligenix, IDT Biologika extend collaboration for biodefense vaccine

Soligenix Inc. extended its collaboration with IDT Biologika for the manufacture of RiVax, Soligenix's proprietary recombinant subunit vaccine developed to protect against exposure to ricin toxin.

Soligenix will advance the formulation and filling processes and will continue development and validation of analytical methods established at IDT to move the program toward a commercially viable scalable technology for the RiVax vaccine.

Soligenix has been developing RiVax, in conjunction with its heat stabilization technology, ThermoVax, as a heat-stable biodefense vaccine. The RiVax project is supported with National Institute of Allergy and Infectious Diseases funding of up to $24.7 million.